Aridis Pharmaceuticals hires Paul-Andre de Lame as Chief Medical Officer

He started his career as an intensive care medical doctor and joined the industry with Merck

Aridis Pharmaceuticals, a US biopharmaceutical company applying proprietary technologies to produce novel anti-infectives, has appointed Paul-Andre de Lame, as Chief Medical Officer.

Dr de Lame is an intensive care medical doctor with experience in cardiovascular medicine and infectious diseases. After several years in clinical practice as an anaesthesiologist and intensive case specialist, he joined Merck where he was charged with furthering the development of enalapril (Vasotec/Renitec) and imipenem-cilastatin (Tienam/Primaxin), then joined Warner Lambert-Parke Davis, where he was instrumental to the success of atorvastatin (Lipitor).

After that he founded Anabase International, which provides regulatory and clinical research services, and later, was co-founder and Chief Medical Officer of Cardiokine.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now